Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2009. The report, issued on March 27, 2009, primarily addresses corporate governance updates regarding the Board of Directors rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a report of a specific corporate event and does not contain financial statements or performance data.
Material Changes
The material change disclosed is a restructuring of Board Committee memberships:
- Mr. Tom De Swaan has been appointed as a member of the Remuneration Committee.
- Mr. De Swaan will cease to be a member of the Corporate Responsibility Committee.
- These changes are effective as of May 20, 2009.
Guidance, Outlook, and Risks
The filing contains no management commentary on financial guidance, future outlook, risks, contingencies, or unusual items. The scope is limited to the announcement of the committee appointment.
Investor Verification Checklist
- Verify the effective date of Mr. Tom De Swaan's new role on the Remuneration Committee (May 20, 2009).
- Confirm the concurrent removal of Mr. De Swaan from the Corporate Responsibility Committee.
- Review subsequent filings (e.g., Form 20-F or quarterly reports) for financial data, as this 6-K does not include it.